Nektar Therapeutics (NKTR): Hedge Fund Sentiment Unchanged

Since Nektar Therapeutics (NASDAQ:NKTR) has sustained falling interest from hedge fund managers, it’s easy to see that there is a sect of money managers that elected to cut their positions entirely last quarter. Interestingly, Bihua Chen’s Cormorant Asset Management got rid of the biggest position of all the investors followed by Insider Monkey, totaling about $28.8 million in stock. Kevin C. Tang’s fund, Tang Capital Management, also dumped its stock, about $3.7 million worth.

Let’s go over hedge fund activity in other stocks similar to Nektar Therapeutics (NASDAQ:NKTR). We will take a look at Commercial Metals Company (NYSE:CMC), Marriott Vacations Worldwide Corp (NYSE:VAC), Simpson Manufacturing Co, Inc. (NYSE:SSD), and American Assets Trust, Inc (NYSE:AAT). This group of stocks’ market values match NKTR’s market value.

As you can see these stocks had an average of 11 hedge funds with bullish positions and the average amount invested in these stocks was $134 million. That figure was $222 million in NKTR’s case. Commercial Metals Company (NYSE:CMC) is the most popular stock in this table. On the other hand American Assets Trust, Inc (NYSE:AAT) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Nektar Therapeutics (NASDAQ:NKTR) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Suggested Articles:
Historical Places To Visit On The East Coast
Easiest and Best Paying Jobs In the World
Most Expensive Beer Brands In India

Disclosure: None